Todd A. Trapp - 25 May 2021 Form 4 Insider Report for ABIOMED INC

Role
Vice President, CFO
Signature
/s/ Ian W. McLeod (by power of attorney)
Issuer symbol
N/A
Transactions as of
25 May 2021
Net transactions value
$0
Form type
4
Filing time
27 May 2021, 16:50:41 UTC
Previous filing
18 May 2021
Next filing
02 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABMD Common Stock, $0.01 par value Award $0 +2,021 +25% $0.000000 10,155 25 May 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABMD Stock Option (right to buy) Award $0 +3,737 $0.000000 3,737 25 May 2021 Common Stock 3,737 $283.88 Direct F2, F3
holding ABMD Stock Option (Right to Buy) 7,000 25 May 2021 Common Stock 7,000 $266.39 Direct F2, F3
holding ABMD Stock Option (right to buy) 6,530 25 May 2021 Common Stock 6,530 $223.90 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25,2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates.
F2 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F3 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.